Onyx Pharmaceuticals, Inc.

249 East Grand Avenue
South San Francisco, CA, 94080

Primary Contacts
N. Anthony Coles, M.D.
President and CEO
Laura A. Brege
Executive Vice President, Corporate Affairs
Matthew K. Fust
Executive Vice President and Chief Financial Officer

Company Profile
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801, an alpha-folate receptor targeted inhibitor of the thymidylate synthase, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing. For more information about Onyx, visit the company’s website at www.onyx-pharm.com.

Company Classification
Bioscience/R&D/Non-Profit conducting R&D

Organization Type
Drug Development

Disease Areas of Focus

Clinical Development Stage
Phase I
Phase II
Phase III